oteseconazole是一种口服给药的真菌CYP51抑制剂，在一年内使90%的女性免于复发。 复发性外阴阴道念珠菌病（RVVC，图片来源：cliniexpert.com） 2021年07月28 ...

A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast ...

Credit: Getty Images. Oteseconazole is a novel oral inhibitor of fungal CYP51. Topline results were announced from two phase 3 trials evaluating oteseconazole (VT-1161; Mycovia Pharmaceuticals ...

C&EN’s Global Top 50 chemical firms for 2024 The US Food and Drug Administration has approved Vivjoa (oteseconazole), Mycovia Pharmaceuticals’ azole antifungal for chronic vaginal yeast infection.

DURHAM, N.C.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent ...

About VIVJOA™ VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are ...

DURHAM – Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for oteseconazole, an oral antifungal product for the ...

NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries - - Oteseconazole’s Qualified Infectious Disease ...

If you continue to have this issue please contact [email protected]. Back to Healio Oteseconazole effectively treated recurrent vulvovaginal candidiasis and prevented acute episodes ...